[go: up one dir, main page]

WO2025133878A1 - Composition de nettoyage et son procédé de préparation - Google Patents

Composition de nettoyage et son procédé de préparation Download PDF

Info

Publication number
WO2025133878A1
WO2025133878A1 PCT/IB2024/062699 IB2024062699W WO2025133878A1 WO 2025133878 A1 WO2025133878 A1 WO 2025133878A1 IB 2024062699 W IB2024062699 W IB 2024062699W WO 2025133878 A1 WO2025133878 A1 WO 2025133878A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
cleansing composition
composition
combination
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/062699
Other languages
English (en)
Inventor
Jayanth Joshi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2025133878A1 publication Critical patent/WO2025133878A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/36—Carboxylic acids; Salts or anhydrides thereof
    • A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/37—Esters of carboxylic acids
    • A61K8/375—Esters of carboxylic acids the alcohol moiety containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/678—Tocopherol, i.e. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/731—Cellulose; Quaternized cellulose derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/737—Galactomannans, e.g. guar; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/10—Washing or bathing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q5/00—Preparations for care of the hair
    • A61Q5/12—Preparations containing hair conditioners

Definitions

  • Cleansing compositions are products designed to clean and purify the skin. These compositions typically come in various forms, such as liquid cleansers, foaming cleansers, creams, gels, or solid bars, and they are used to remove dirt, excess oil, makeup, and impurities from the skin.
  • the specific ingredients and formulations of these compositions can vary widely depending on the type of skin they are designed for and the desired effects.
  • ⁇ cleansing compositions Common ingredients found in skin cleansing compositions include water, surfactants, emollients and humectants along with some preservatives in few cases to extend the shelf life of the product and prevent the growth of harmful microorganisms. Nevertheless, several skin cleansing compositions include Alpha Hydroxy Acids (AHAs) as an active ingredient along with various types of surfactants. Few non-foaming rinse-off formulations contain non-ionic surfactants. There are other non-foaming formulations known in the art which are not waterbased and rely on alcohols as active ingredients and as a solvent base.
  • AHAs Alpha Hydroxy Acids
  • Another objective of the present invention is to provide a cleansing composition with a pH matching the skin's natural pH to avoid irritation or disruption of the skin's protective barrier.
  • viscosity adjusting agent a skin conditioner, an antibacterial agent, an antioxidant, a fragrance, a colorant, a chelating agent, a humectant, an emollient, an insoluble material, a pearlescent material, a diluent, and a combination thereof; and vi. obtaining the cleansing composition.
  • the present invention discloses a cleansing composition
  • a cleansing composition comprising; i. a combination of Alpha Hydroxy Acids (AHA) organic; ii. a salt of a hydroxy acid; iii. a natural humectant iv. rheology modifier; and v. a natural preservative, and vi. a solvent.
  • AHA Alpha Hydroxy Acids
  • the pH of said composition ranges from 4 to 5.
  • said cleansing composition further comprises, a viscosity adjusting agent, a skin conditioner, an antibacterial agent, an antioxidant, a fragrance, a colorant, a chelating agent, an insoluble material, a pearlescent material, a diluent, and combinations thereof.
  • a viscosity adjusting agent helps in adjusting the pH and no other component was used to adjust the pH of the composition.
  • said cleansing composition is dermatologist-tested and clinically proven.
  • the present invention discloses a method of preparing the cleansing composition as claimed in claim 1, comprising the steps of: i. dispersing and neutralizing xanthan gum in an amount of 0.72% in 90.57% ml deionized water ii. adding citric acid and lactic acid in a range of 0. 1% to 5%; with constant stirring to obtain mixture 1 ; iii. providing trisodium citrate in the range of 6-8% and glycerin in a range of 1.5- 2.5% to mixture 1; iv. adding preservatives in an amount of 0. 1-0.3%. v.
  • viscosity adjusting agent a skin conditioner, an antibacterial agent, an antioxidant, a fragrance, a colorant, a chelating agent, a humectant, an emollient, an insoluble material, a pearlescent material, a diluent, and a combination thereof; and vi. obtaining the cleansing composition.
  • all the steps are performed at room temperature.
  • the optional ingredients are used in an amount ranging from 0. 1-0.2 %.
  • AHAs Alpha Hydroxy Acids
  • the AHAs are the active ingredients of the composition and are known to have antimicrobial and cleansing properties. Care should be taken that the concentration of the AHAs should not exceed beyond the optimal point to make them non-irritant to the skin.
  • the present composition also takes into consideration that AHAs can lead to skin sensitization under sunlight at elevated concentrations. Hence, care has been taken to standardize the concentration of the selected AHAs as to be as safe and effective as possible.
  • a combination of two Alpha Hydroxy Acids (AHAs) are selected from the following:
  • Salts of Hydroxy Acids are widely used in cleaning composition as pH adjuster and cleansing enhancers.
  • the salts are used to carefully adjust he pH of the composition to suit the nominal skin pH of 4.5 to 5.5. the salts combine with the AHAs to provide improved cleansing performance against stains.
  • a salt of a Hydroxy Acid is chosen from the following list:
  • a natural humectant for the present composition is selected from the below list:
  • the viscosity of the composition needs to be sufficiently high as to make the product not to run-off of the skin when applied and help spread the product in the absent of a surfactant.
  • the current composition achieves the desired viscosity without compromising on clarity.
  • a rheology modifier is chosen from the below list:
  • Natural preservatives are used in the composition to protect it from development of microbes and to prolong the shelf life.
  • a combination of preservatives selected from the following:
  • the process is conducted at room temperature throughout.
  • Stepl neutralize 7.2 g xanthan gum in 905.7 ml of D.I water at room temperature with constant stirring.
  • Step2 after all the xanthan gum has neutralized add citric acid (27 g) and lactic acid (8.1 g) with constant stirring.
  • Step3 Add Trisodium citrate (27 g) to the mixture with constant stirring.
  • Step4 Add Glycerin (21 g) with constant stirring.
  • Step5 Add colorant and fragrance (Approx. 2g) with constant stirring.
  • Step6 Add preservative mixture of potassium sorbate and sodium benzoate of (2 g) and stir until completely dissolved.
  • Xanthan gum is dispersed in Deionized water until completely neutralized. Citric acid and Lactic acid are added with constant stirring. Trisodium Citrate is added followed by Glycerin. Suitable colorant and Fragrance are added as required. Preservatives are added to the composition at the end.
  • composition is valid only if the above key specifications are met.
  • Example 2 Assessment of anti-inflammatory activity of test product upon LPS induction in THp-1 celts Gell line THP-1 (ATCC No: TIB-202rM- Human monocytes)
  • Example 5 Differentiation of THP-I cells to Macrophage using PMA as differentiating agent and induction of inflammation using LPS
  • the cells were aspirated from the 80% confluence culture flask and centrifuged at 1500 rpm for 5 mins. The cell pellet was then resuspended in 1 ml of RPMI complete growth medium and 2 X 105 cells/well was seeded to each well of the 12-well microtiter plate. After 24 hrs of incubation, pMA (25 ng/ml) was added to'12-well plate to differentiate THP-1 cells and incubated for 24 hrs. After incubation, differentiated cells were pretreated for 4 hrs with various concentrations of test compounds followed by LPS (10 ng/ml) stimulation for 12 hrs. Dexamethasone (2 pg/ml) was used as a positive control. Post incubation, cells were harvested for gene expression study further.
  • Treated cells were dissociated and rinsed with sterile IX PBS and centrifuged. The supernatant was decanted and 0.1 ml of TRlzol was added and gently mixed by inversion for 1 min. Samples were allowed to stand for 10 minutes at room temperature. To this 0.75 ml chloroform was added per 0.1 ml of TRlzol used. The contents were vortexed for 15 seconds. The tube was allowed to stand at room temperature for 5 mins. The resulting mixture was centrifuged at 12,000 rpm for 15 mins at 4"C.
  • RNA yield was quantified using Spectra drop (Spectramax i3x, Molecular devices, USA).
  • the cDNA was synthesized from 500 ng of RNA using the oDNA synthesis kit from Prime script RT reagent kit (TAKARA) with oligo dT primer according to the manufacturer's instructions.
  • the reaction volume was set to 20 pl and cDNA synthesis was performed at 50 oC for 30 min, followed by RT inactivation at 85oC for 5 min using applied biosystems, Veritii.
  • the cDNA was further used for realtime PCR analysis.
  • the PCR mixture (final volume of 20 pl) contained 1 .4 pl of cDNA, 10 pL of SyBr green Master mix and 1 pM of respective complementary forward and reverse primers specific for respective target genes.
  • the reaction was carried out with enzyme activation at 95oC for 2 minutes followed by 2 step reaction with initial denaturation and annealing cum extension step at 95"C for 5 seconds, annealing for 30 seconds at appropriate respective temperature amplified for 39 cycles followed by secondary denaturation at 95 "C for 5 seconds, 1 cycle with melt curve capture step ranging from 65'C to 95'C for 5 secs each.
  • the obtained results were analyzed and fold expression or regulation was calculated.
  • Table 4 Primer Details
  • Table 7 Relative normalized expression of IL-6 gene (FIG. 4)
  • the RT PCR analysis of target genes TNF-o and IL-6 were carried out and fold regulation was determined. The results suggested the increase in TNF-o and IL-6 with 11.16- and 14.72-fold expression respectively when exposed to LPS as compared to control differentiated cells (FIG. 1 and 5). On other hand, there is decrease in expression of TNF-o with 7.96 and 6.55 when cells were treated with Sample at 0.3% and 1.1 % respectively. Likewise, the gene expression of IL-6 also got downregulated by 0.58 and 0.57-fold when cells were treated with lower and higher concentration of Liquid hand wash sample (FIG. la and 15). While reference positive control Dexamethasone at 2 pglml concentration showed significant down regulation of both TNF-o and 1L6 by 2.98 and 0.21fold respectively as compared to disease control (FIG. 3 and FIG. 4).
  • Hand wash Liquid 290gms has shown >99.999, >99.999, >99.999, >99.999, >99.999 & >99.999, antimicrobial activity, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, Candida albicans, Aspergillus niger & Staphylococcus epidermr.s respectively when analyzed as per AATCC 100-2012 test method.
  • the foregoing examples are merely illustrative and are not to be taken as limitations upon the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the scope of the invention.
  • the disclosed invention performs the function of skin cleansing effectively with a simpler formulation without the use of complex surfactant blends and with natural or nature identical ingredients that readily biodegrade in nature after usage.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Cosmetics (AREA)

Abstract

La présente invention divulgue une composition de nettoyage comprenant une combinaison d'alpha-hydroxyacides (AHA) organiques; un sel d'un hydroxyacide; un humectant naturel; un modificateur de rhéologie; un conservateur naturel et un solvant. La présente invention concerne également un procédé de préparation de la composition de nettoyage. L'invention divulguée réalise la fonction de nettoyage de la peau efficacement avec une formulation plus simple sans utiliser de mélanges de tensioactifs complexes et avec des ingrédients naturels ou nature-identiques qui se biodégradent facilement dans la nature après utilisation, exempts de produits chimiques agressifs et appropriés pour tous les types de peau.
PCT/IB2024/062699 2023-12-22 2024-12-16 Composition de nettoyage et son procédé de préparation Pending WO2025133878A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202341087988 2023-12-22
IN202341087988 2023-12-22

Publications (1)

Publication Number Publication Date
WO2025133878A1 true WO2025133878A1 (fr) 2025-06-26

Family

ID=96136535

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/062699 Pending WO2025133878A1 (fr) 2023-12-22 2024-12-16 Composition de nettoyage et son procédé de préparation

Country Status (1)

Country Link
WO (1) WO2025133878A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017218A1 (en) * 2013-07-15 2015-01-15 The Procter & Gamble Company Cleansing composition having a preservative system and a wet wipe comprising the cleansing composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20150017218A1 (en) * 2013-07-15 2015-01-15 The Procter & Gamble Company Cleansing composition having a preservative system and a wet wipe comprising the cleansing composition

Similar Documents

Publication Publication Date Title
CN100374099C (zh) 抗微生物组合物
CA2467244C (fr) Utilisation d'un tensioactif cationique en tant qu'amplificateur de l'activite antimicrobienne dans des deodorants et preparations d'hygiene bucco-dentaire
JP3615218B2 (ja) 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
JP2003515615A (ja) 治療用抗菌剤組成物
US12295366B2 (en) Preservation of personal care compositions
WO2004028520A1 (fr) Bactericides antiseptiques et cosmetiques, medicaments et produits alimentaires contenant ces bactericides antiseptiques
KR100541271B1 (ko) 국소적 사용을 위한 항균조성물
JP5637987B2 (ja) 防腐剤組成物
WO2007103441A2 (fr) Esters antimicrobiens
CN111031794B (zh) 含有4-(3-乙氧基-4-羟苯基)丁-2-酮和有机酸化合物的抗微生物混合物、以及含有该抗微生物混合物的化妆品组合物
JP2025507044A (ja) カプリルヒドロキサム酸、４’－ヒドロキシアセトフェノン及びポリオールを含む皮膚外用剤用保存剤、及びそれを含む化粧料組成物
CN102264225A (zh) 抗微生物剂、含有其的组合物和产品以及使用该组合物和产品的方法
FR3064473A1 (fr) Ingredient protecteur de l'equilibre de la flore microbienne cutanee et/ou mucosale
JP2012500209A (ja) 抗菌性ゲル製剤
JP2004307484A (ja) 防腐殺菌剤並びに該防腐殺菌剤を配合した化粧料、医薬品及び食品
WO2025133878A1 (fr) Composition de nettoyage et son procédé de préparation
CN107592809A (zh) 皮肤外用剂用保存剂及含有其的化妆品组合物和药物组合物
KR102262466B1 (ko) 락토바실러스 애시도필러스 발효액 및 방부제를 포함하는 방부 시스템
FR2967054A1 (fr) Systeme conservateur
KR20220058468A (ko) 알칸디올, 및 카프릴릴글리세릴에터 또는 에틸헥실글리세린을 포함하는 피부 외용제용 보존제 및 이를 포함하는 화장료 조성물
CN111031793B (zh) 含有4-(3-乙氧基-4-羟苯基)丁-2-酮和氯苯甘醚的抗微生物混合物、以及含有该抗微生物混合物的化妆品组合物
RU2729405C1 (ru) Противомикробная смесь, содержащая 4-(3-этокси-4-гидроксифенил)бутан-2-он, и косметическая композиция, содержащая ее
US20230372227A1 (en) Preservative comprising polylysine and caprylyl glyceryl ether for external-use skin formulations and cosmetics composition comprising same
KR20120086123A (ko) 항균성 피부 외용제 조성물
KR20100089698A (ko) 화장료 조성물

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24906686

Country of ref document: EP

Kind code of ref document: A1

DPE1 Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101)